Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis

…, G Shanbhag, J Puttur, V Shinde…

Index: Shinde, Vikas N.; Ugarkar, Bheemarao G.; Ghorpade, Sandeep R. Journal of Chemical Research, 2013 , vol. 37, # 1 p. 53 - 54

Full Text: HTML

Citation Number: 16

Abstract

DNA gyrase is a clinically validated target for developing drugs against Mycobacterium tuberculosis (Mtb). Despite the promise of fluoroquinolones (FQs) as anti-tuberculosis drugs, the prevalence of pre-existing resistance to FQs is likely to restrict their clinical value. We